Group B streptococcus type II polysaccharide-tetanus toxoid conj

Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

4241931, 4241981, 4242031, 530403, 530813, 530825, A61K 3909

Patent

active

058434615

ABSTRACT:
This invention relates to antigenic conjugate molecules comprising the capsular polysaccharide of Group B streptococcus type II which are covalently linked to protein. This invention also relates to vaccines and methods of immunizing mammals, including humans against infection by Group B streptococcus type II (GBS II). Multivalent vaccines comprising the conjugate molecules of this invention and antigens to other pathogenic bacteria are also claimed.

REFERENCES:
patent: 4207414 (1980-06-01), Kasper
patent: 4284537 (1981-08-01), Beachley
patent: 4324887 (1982-04-01), Kasper
patent: 4356170 (1982-10-01), Jennings
patent: 4356263 (1982-10-01), Kasper
patent: 4367221 (1983-01-01), Kasper
patent: 4367222 (1983-01-01), Kasper
patent: 4425330 (1984-01-01), Norcross et al.
patent: 4619828 (1986-10-01), Gordon
patent: 4757134 (1988-07-01), Blake et al.
patent: 4789735 (1988-12-01), Frank et al.
patent: 4902506 (1990-02-01), Anderson et al.
patent: 5302386 (1994-04-01), Kasper
patent: 5367223 (1994-11-01), Kasper
Attachment A (Work Statement) from Request for Proposal No. NIH-NIAID-DMID-92-13, issued by the Department of Health and Human Services for the National Institutes of Health on Jan. 21, 1992, entitled, "Prevention of Group B Streptococcal Infections in Neonatal and Infant Populations".
Abstract of Grant No. 2R37A23339-08, "Immunochemistry of Group B streptococcus polysaccharides (human, mice, rabbits)", Kasper, D.L., Principal Investigator, Fed. Research in Progress, printout of Jan. 26, 1993 for fiscal year 1992.
Abstract of Grant No. 5R01AI30628-02, "Prevention of perinatal group B streptococcal infections (human, mice, rabbits)", Kasper D.L., Principal Investigator, Fed. Research in Progress, printout of Jan. 26, 1993 for fiscal year 1992.
Baker, C.J., "Immunization to Prevent Group B Streptococcal Disease: Victories and Vexations", Journal of Infectious Disease, vol. 161, No. 5, pp. 917-921, May 1990.
Bittle, J.L., et al. "Vaccines Produced by Conventional Means to Control Major Infectious Diseases of Man and Animals", Adv. Vet. Sci. Comp. Med., vol. 33, pp. 1-63, Feb. 1989.
Coleman, R.T., et al., "Prevention of Neonatal Group B Streptococcal Infections: Advances in Maternal Vaccine Development", Obst. Gynec., vol. 80, No. 2, pp. 301-309, Aug. 1992.
Dintzis, "Rational Design of Conjugate Vaccines", Pediatric Research, vol. 32, No. 4, pp. 376-385, Oct. 1992.
Feldman, et al. "The immune response to the group B streptococcus", Reviews in Medical Microbiology, vol. 3, No. 1, Jan. 1992, pp. 52-58.
Givner, et al. "Pooled Human IgH hyperimmune for type III Group B Streptococci: Evaluation against multiple strains in vitro and in experimental diseases", J. Infectious Diseases, vol. 163, pp. 1141-1145, May 1991.
Insel, R.A., "Maternal Immunization of Prevent Neonatal Infections", New England Journal of Medicine, vol. 319, No. 18, pp. 1219-1220, Nov. 1988.
Lerner, R.A., et al. "The Development of Synthetic Vaccines", The Biology of Immunologic Disease, Dixon, F.J., et al., eds., Sinauer Associates: Sunderland, MA, pp. 331-338, 1983.
Madoff, et al., "Maternal Immunization of Mice with Group B Streptococcal Type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple stereotypes", J. Clin. Invest., vol. 94, pp. 286-292, Jul. 1994.
Madoff, L.C., et al., "Protection of Neonatal Mice from Group B Streptococcal Infection by Maternal Immunization with Beta C Protein", Infect. Immun., vol. 60, No. 12, pp. 4989-4994, Dec. 1992.
Paoletti, L.C., et al. "Group B Streptococcus Type III Glycoconjugate Vaccines", Trends in Glycosci. Glycotech., vol. 4, No. 17, pp. 269-278, May 1992.
Paoletti, et al. "Immunogenicity of Group B Streptococcus Type III Polysaccharide-tetanus Vaccine in Baboons", Infection and Immunity, vol. 64, No. 2, pp. 677-679, Feb. 1996.
Wilkinson, H.W., et al. "Type-Specific Antigens of Group B Type Ic Streptococci", Infect. Immun., vol. 4, No. 5, pp. 596-604, Nov. 1971.
Ward et al, "Haemophilus influenzae Vaccines" in Vaccines Plotkin et al eds, W.B. Saunders Co. Philadelphia pp. 300-332, 1988.
Baker et al, Rev. Infec. Dis. 7(4):458-467, 1985.
Baker et al, New Eng. J. Med. 319(18): 1180-1185, 1988.
Boyer et al, Clin Res., 34(4) 962 A, 1986.
Wessels et al, Infect. Immun, 57(4):1089-1094, 1989.
Kasper et al, J. Clin Invest, 72:260-269, 1983.
Jenning et al, J. Biol. Chem. 258(3): 1793-1798, 1983.
Jennings et al, Biochemistry, 20(16): 4511-4518, 1981.
Sarvamangular et al, Proc. Natl Acad Sci, 88:7175-7179, 1991.
Heimas et al, The Opsomic Antibody Response of Female Rats to Type III Group B Streptococcal.
Immunization: a model for maternal Immunity, Vet. Immunol. Immunopath. 24:79-89, 1990.
Reuter et al, A Detailed Study of the Periodate Oxidation of Sialic Acids in Glycoproteins, Glycoconjugate J 6:35-44, 1989.
Facklam et al, "Streptococci and Aerococci" in Manual of Clinical Immunology, 4 ed. Lennette et al eds, American Society for Microbiology, 1985, pp. 154-175.
Wesseles et al, Immunogenicity in Animals of a Polysaccharide-Protein Conjugate Vaccine against Type III Group B Streptococcus; J. Clin. Invest 86:1428-1433, 1990.
Harold J. Jennings and C. Lugowski, "Immunochemistry of Groups A, B and C Meningococcal Polysaccharide Tetanus Toxoid Conjugates", The Journal of Immunology, 127:1011-1017 (1981).
Dick and Beurret (1989) "Glyconjugates of Bacterial Carobhydrafe Antigens--A Survey and Consideration of Designa dn Preparation Facts" Conjugate Vaccines) In Contrib. Microbiol. Immunol (Cruse, JM and Lewis, RE Tr. (eds.) Basel Karger vol. 10:48:114.
Jennings, (1983) "Capsular Polysaccharrides as Human Vaccines" In Advances Carobhydrate Chemistry and Biochemistry, vol. 41:155-207, Academic Press Inc. NY NY.
Paoletti (1992) Effects of Chain Length on the Immunogenicity in Rabbits of Group B Streptococcus Type III Oligosaccharride--Tetanus Toxoid Conjugate. J. Clin. Invest. 89:203-209.
Wessels, et al. (1989) "Isolation and Characterization of Type IV Group B Streptococcus Capsular Polysaccharide" Infection and Immunity, vol. 57, No. 4:1089-1094.
Kasper, et al. (1983) "Immunochemical Analysis and Immunogenicity of the Type II Group B Streptococcal Capsular Polysaccharide." J. Clin Invest, vol. 72:260-269.
Jennings, et al. (1982) "Structural Determination of the Capsular Polysaccharide Antigen of Type II Group B Streptococcus". The Journal of Biological Chemistry, vol. 258:1793-1798.
Paoletti, et al. (1990) An Oligosaccharide-Tetanus Toxoid Conjugate Vaccine against Type II Group B Streptococcus. The Journal of Biological Chemistry, vol. 265:18278-18283.
Rodewald, et al. (1992) "Neonatal Mouse Model of Group B Streptococcal Infection", The Journal of Infectious Diseases, vol. 166:635-9.
Paoletti (1992) "Group B Stretoccus Type II Polysaccharride--Tetanus Toxoid conjugate Vaccine" Infection and Immunity, vol. 60:4009-4014.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Group B streptococcus type II polysaccharide-tetanus toxoid conj does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Group B streptococcus type II polysaccharide-tetanus toxoid conj, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Group B streptococcus type II polysaccharide-tetanus toxoid conj will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2393562

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.